ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-BAFFR Monoclonal Antibody ESG206

Its studies are mostly in Lupus Erythematosus, Systemic · Purpura, Thrombocytopenic, Idiopathic, led by Shanghai Escugen Biotechnology.

Drug pageAnti-BAFFR Monoclonal Antibody ESG206: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 25, 20255 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Escugen Biotechnology53 open or runningphase 2since Feb 25, 2025Feb 18, 2022Dec 31, 2027phase 2 · NCT07375524

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2022First study: phase 1 study in B-cell Lymphoid MalignanciesFirst studyNCT05263739
  2. Apr 10, 2023Phase 1 study in B-cell Lymphoid MalignanciesNCT05822843 · 13 enrolled · China
  3. Feb 25, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06853444 · 84 planned · China
  4. Jan 21, 2026Phase 2 study in Primary Sjögren SyndromeNCT07375524 · 40 planned · China
  5. Aug 7, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07760155 · 40 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Primary Sjögren SyndromeNCT07375524
  2. Mar 31, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07760155

TargetBeta

TNFRSF13C →read by rule
“A monoclonal antibody that is directed against the tumor-associated antigen (TAA) B-cell activating factor receptor (BAFFR; tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BLyS receptor 3; BR3), ”NCIt, by rule

Other programs on TNFRSF13C

ProgramCompanyFurthest phaseStudies
ianalumabNovartisphase 334
Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199ruleEli Lillyphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07760155Lupus Erythematosus, Systemic · China2Not yet recruitingMar 31, 202840
NCT07375524Primary Sjögren Syndrome · China2Not yet recruitingDec 31, 202740
NCT06853444Purpura, Thrombocytopenic, Idiopathic · China2RecruitingMar 31, 202684
NCT05822843B-cell Lymphoid Malignancies · China1CompletedJan 22, 202513
NCT05263739B-cell Lymphoid Malignancies1WithdrawnAug 20260

How it is read

Names in the registry

  • “ESG206”, 10 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.